What is Inne?
Inne offers a novel approach to reproductive health with its saliva-based progesterone tracking Minilab. This CE-certified device provides personalized hormone insights, empowering women to monitor their fertility and reproductive health from home. With a reported 92% effectiveness rate, Inne aims to be a leading provider of scientifically-backed, non-hormonal contraceptive solutions, targeting health-conscious individuals seeking innovative alternatives.
How much funding has Inne raised?
Inne has raised a total of $18.8M across 1 funding round:
Series A
$18.8M
Series A (2019): $18.8M with participation from Monkfish Equity, DSM Venturing, Taavet Hinrikus, Calm/Storm Ventures, Rolf Schromgens, Tom Stafford, Blossom Capital, and Borski Fund
Key Investors in Inne
Monkfish Equity
Monkfish Equity is an investment firm that supports early-stage European startups by providing seed and growth capital, focusing on innovative ideas and building strong relationships with entrepreneurial teams.
Blossom Capital
Blossom Capital is a VC fund concentrating on early-stage investments in consumer and enterprise sectors, particularly in finance, design, marketplaces, and API-first companies across Europe.
Borski Fund
Borski Fund is a venture capital fund that invests in companies led by women or those offering products and services for women, aiming to reduce the gender gap in investment.
What's next for Inne?
The recent major strategic investment in Inne signals a pivotal moment for the company, likely enabling expansion of its product development, market reach, and technological capabilities. This capital infusion, part of its $18.8M in total funding, suggests a move towards scaling operations and solidifying its position in the competitive HealthTech landscape. Future developments may include further clinical validation, broader market penetration, and potential integration with other digital health platforms.
See full Inne company page
